© 2017

TRAIL, Fas Ligand, TNF and TLR3 in Cancer

  • Olivier Micheau
  • Provides an up-to-date overview of TNF family signal transduction with a special emphasis on TRAIL and Fas L

  • Deals with cell biology, immunology and oncology and in particular drug-resistance mechanisms, as well as prometastatic potential, related to the cell biology of the downstream signaling components of the TNF superfamily

  • Addresses how post-translational modifications of TNF related members or their cleavage by proteases affect their signaling capacity


Part of the Resistance to Targeted Anti-Cancer Therapeutics book series (RTACT, volume 12)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Jessica Wagner, Christina Leah Kline, Wafik El-Deiry
    Pages 1-25
  3. Lubna Danish, Daniela Stöhr, Peter Scheurich, Nadine Pollak
    Pages 27-57
  4. Laurence Dubrez, Simone Fulda
    Pages 59-77
  5. James Sledziona, Vivek M. Rangnekar
    Pages 91-106
  6. Amanda Poissonnier, Patrick Legembre
    Pages 131-157
  7. Yann Estornes, Toufic Renno, Serge Lebecque
    Pages 159-185
  8. Faustino Mollinedo, Consuelo Gajate
    Pages 187-227
  9. Fatima Bilal, Michaël Pérès, Nathalie Andrieu-Abadie, Thierry Levade, Bassam Badran, Ahmad Daher et al.
    Pages 229-245
  10. François Bertaux, Dirk Drasdo, Grégory Batt
    Pages 291-307
  11. Back Matter
    Pages 309-317

About this book


This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors.



Editors and affiliations

  • Olivier Micheau
    • 1
  1. 1.INSERM, LNC UMR 1231DijonFrance

About the editors

Dr. Olivier Micheau is a research director of the INSERM (French National Institute of Health), UMR1231. He received his PhD in  Biochemistry and Molecular and Cellular Biology in 1999 from the University of Burgundy, France. He next moved as a post-doctoral fellow in Jurg Tschopp’s laboratory in Epalinges, Switzerland, from 1999 to 2003, where he elucidated the molecular mechanisms underlying TNFR1’s dual signaling ability. He described for the first time TNFR1 cytosolic pro-apoptotic complex II. In 2003 he joined the INSERM unit U517 headed by Professor E. Solary in Dijon, France, as an INSERM researcher. Member of several scientific councils, including INSERM CSS3 (2012-2016) and Fondation ARC pour la recherche sur le cancer, a French Charity (since 2015), he is also Associate Editor of the British Journal of Pharmacology since 2012. His scientific interest focuses on TRAIL receptor signaling and its use in cancer therapy.

Bibliographic information

  • Book Title TRAIL, Fas Ligand, TNF and TLR3 in Cancer
  • Editors Olivier Micheau
  • Series Title Resistance to Targeted Anti-Cancer Therapeutics
  • Series Abbreviated Title Resistance to Targeted Anti-Cancer Therapeutics
  • DOI
  • Copyright Information Springer International Publishing AG 2017
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences Biomedical and Life Sciences (R0)
  • Hardcover ISBN 978-3-319-56804-1
  • Softcover ISBN 978-3-319-86006-0
  • eBook ISBN 978-3-319-56805-8
  • Series ISSN 2196-5501
  • Series E-ISSN 2196-551X
  • Edition Number 1
  • Number of Pages XIII, 317
  • Number of Illustrations 5 b/w illustrations, 35 illustrations in colour
  • Topics Cancer Research
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods